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There is a great unmet need for health technologies to address diseases of the poor in developing 
countries.  At the same time, there is a rapidly growing capability to undertake health innovation* 
in many developing countries (Innovative Developing Countries - IDCs).  The more advanced 
IDCs have the greatest capacity to develop, manufacture, ensure safety, and market new health 
products and to develop, test and introduce new health policies or strategies.  They are 
distinguished by their rapidly growing strength in health innovation as illustrated by increasing 
patenting and publishing activities; increasing investments in technology by both the public and 
private research based sectors; rapidly growing number of health technology companies†; and 
proactive health systems able to analyze, evaluate and adopt new practices and technologies.   
 
This innovation capability provides a currently underleveraged opportunity to accelerate the 
development of new products, policies or strategies for diseases of the poor.  We are therefore 
calling for the formation of an Initiative for Health Product Innovation in Developing Countries. 
Its primary mission will be to accelerate the translation of new knowledge into health 
innovations relevant to the diseases of the poor and to economic growth, taking into account 
national priorities and sensitivities.  The Initiative could promote innovation, within and among 
IDCs, through programs to:  (i) support research on health innovation systems; (ii) promote 
collaboration and coordination among countries to develop, disseminate and implement good 
practices and policies; and (iii) implement demonstration projects. 
 
Such an Initiative would help maximize existing and growing investments by developing 
countries in health research, and complement global efforts to address health disparities and 
achieve the Millennium Development Goals.1 
 
Southern Needs, Northern Response and Global Strategies 
Recent evidence shows that improved health is more than a consequence of development.  It is a 
central input into economic and social development and poverty reduction.  Good health, 
economic development and individual economic well being are intimately interdependent.  The 
importance of investing in health cannot be overstated.2  The magnitude of the health problems 
facing the poor in developing countries are immense.3,4  Approximately 10 million children die 
each year with “under-nutrition as an underlying cause of child deaths associated with infectious 
diseases, the effects of multiple concurrent illnesses, and recognition that pneumonia and 
diarrhea remain the diseases that are most often associated with child deaths.”5  In addition, 
global health experts are increasingly recognizing the growing relative importance of chronic 
diseases in the developing world where, in contrast to the infectious diseases that primarily affect 
children, the elderly are the most vulnerable.  Chronic diseases are the world’s largest cause of 
 
* We use the term ‘health innovation’ to include the development of new drugs, vaccines and diagnostics as well as 
new techniques in process engineering/manufacturing and new approaches/policies in health systems and services. 
† Throughout this paper, we will refer to specific developing countries.  These are illustrative and there are many 
additional countries with strengths in innovation.   
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death with 29 million deaths worldwide.  The leading chronic diseases are cardiovascular disease, 
cancer, chronic respiratory disease, and diabetes.6   
 
There are many interventions and strategies for improving health including strengthening health 
systems to improve the delivery of goods and services, education about desirable individual 
behavior, and introduction of water and sanitation systems.  However, limitations of existing 
technologies, or the absence of appropriate technologies and other innovations, impede the 
achievement of desired health improvement goals.  All health interventions draw upon 
innovations as essential tools to achieve the desired health improvement outcome.  Such 
innovations include vaccines to prevent HIV, malaria, respiratory, and diarrhea (?? Please check) 
diseases; drugs to treat TB, malaria, cancers, and diabetes; other hardware such as weighing 
scales; software such as disease surveillance systems; and diagnostics and medical devices.  
These are a necessary part of a broader package of interventions including improvements in 
health delivery, surveillance, and policy formulation to improve the health of those most in need 
in the developing world.   
 
Efforts to accelerate the development and distribution of health products for diseases of the poor 
have intensified over the past decade.  Product development public private partnerships (PD-
PPPs) have been established to develop new vaccines and drugs against HIV, malaria, TB , 
diarrhea and other infectious diseases, and related diagnostics and medical devices.  These 
partnerships include the International AIDS Vaccine Initiative (IAVI), the International 
Partnership for Microbicides (IPM), the Medicines for Malaria Venture (MMV), the Malaria 
Vaccine Initiative (MVI), the Global Alliance for TB Drug Development (TB Alliance), the 
Aeras Global TB Vaccine Foundation, the Foundation for Innovative New Diagnostics (FIND), 
the Drugs for Neglected Diseases Initiative (DNDi) and the Institute for OneWorld Health.  
These initiatives have made significant progress, but are still relatively young and have therefore 
not yet achieved their intended goals.7 
 
In addition to the PD PPPs, major global funds have been also established over the past five 
years to procure and distribute existing drugs and vaccines.  These include the Vaccine Fund that 
works with the Global Alliance for Vaccines and Immunizations (GAVI) and the Global Fund to 
Fight AIDS, Tuberculosis and Malaria.  Sustained and increasing support from donors will be 
needed for product development and procurement efforts to have their desired impact over the 
next decade.  Access by the poor, either to existing or new products, depends upon numerous 
factors, but especially health delivery systems.  The need for more attention, research and 
resources in this area was the subject of the annual Global Forum for Health Research, and the 
WHO-Mexico Ministerial Summit on Health Research, both held in Mexico City November 16-
20, 2004. 
Growing Capabilities of Developing Countries in Health Innovation  
One commonly identified impediment to effective health systems in developing countries is the 
difficulty of translating promising product concepts into affordable and accessible products.  
However, at least in some developing countries, this difficulty is beginning to be addressed.  The 
rapidly growing health innovation capabilities of some developing countries represent a 
phenomenon that should complement the PD PPP efforts described above.   
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The concept of “health innovation systems” encompasses interlinked components including 
education, R&D, manufacture, domestic and export markets, intellectual property (IP) 
management, regulatory systems and the national policies that affect all of these (including 
public-private partnerships)8 9.  An effective health innovation system, extending from concept 
research through delivery at the program and health systems level, depends upon the design and 
implementation of policies that recognize the dynamic linkages among all components of the 
system.   
 
Developing countries themselves are building innovative capacity for new health technologies, 
products and services.  Collectively they already invest at least $2.5 billion per year in health 
research.10  This compares with about $200 million per year by various PD PPPs.11  Public and 
private sectors in some developing countries are also working to build innovative capacities 
through the establishment of IP management systems, drug and vaccine manufacturing facilities, 
and regulatory capabilities. 
 
Some developing countries are more scientifically advanced and have the greatest capacity to 
develop, manufacture, ensure safety, and market new health products.  Innovation can occur in 
any locality, and this paper highlights recent dramatic progress in a few advanced “innovative 
developing countries.” 12 
 
Mashelkar has introduced a construct for understanding the special category of (??please check; I 
thought we don’t need the word ‘advanced’ here) IDCs (Table 1).13  This modular construct adds 
nuance to the usual dichotomy between rich and poor countries.  Countries could be arrayed 
along a continuous spectrum from higher to lower economic strength, and from higher to lower 
innovation capability.  While economic strength is easily measured, and reasonably well-
understood, innovation capability presents more difficulty. 
 
Table 1.  Economic Strength and Innovation Capability (adapted from Mashelkar) 
 








Natural Resource Rich  
Countries and small OECD 
countries 
G8 
Least Developed Countries 
and other non-IDC 
Developing Countries 
Advanced IDCs 
Advanced IDCs are the countries in the lower right quadrant.14 
Economic strength is measured by GDP per capita. 
(then, who are the non-advanced IDCs?  Or, We had better define clearly them before here) 
 
Given the complex set of activities involved in the innovative process, measurement of 
“innovative capability” must be based on several indicators.  Cross-country comparative data for 
a broad set of measures are limited.  One often used measure of innovation is the number of US 
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patents issued.15  Innovative efficiency, by extension, may be measured by the number of US 
patents per GDP/capita.  Patents do not necessarily translate into products, and US patents 
represent only a subset of all innovation in a country.  Thus, while instructive, this is an indirect 
measure of innovation capability.  However, because of the global dominance of US markets, it 
has the advantage of creating a common yardstick against which to measure all countries. 
 
Table 3 shows the top 25 countries in the world by rank order, analyzed for health related 
inventions only.  Note that India and China are at 3rd and 4th places.  Other developing countries 
on the list are Brazil, South Africa, Thailand, Malaysia, Indonesia and Argentina (in rank order). 
 
 







US patents per 
GDP per capita 
1 United States G8, OECD 50000 (est.) 36,006 1.389 
2 Japan G8, OECD 36889 31,407 1.175 
3 India Advanced IDC 444 487 0.913 
4 China Advanced IDC 724 989 0.732 
5 Germany G8, OECD 12960 24,051 0.539 
6 Korea, Rep. OECD 4246 10,006 0.424 
7 France G8, OECD 4906 24,061 0.204 
8 Canada G8, OECD 4368 22,777 0.192 
9 United Kingdom G8, OECD 4920 26,445 0.186 
10 Italy G8, OECD 2147 20,528 0.105 
11 Brazil Advanced IDC 209 2,593 0.081 
12 Israel HIE 1231 15,792 0.078 
13 Sweden OECD 1958 26,929 0.073 
14 South Africa Advanced IDC 142 2,299 0.062 
15 Australia OECD 1105 20,822 0.053 
16 Switzerland OECD 1917 36,687 0.052 
17 Belgium OECD 1055 23,749 0.044 
18 Finland OECD 945 25,295 0.037 
19 Austria OECD 657 19,749 0.033 
20 Thailand Advanced IDC 64 2,060 0.031 
21 Singapore HIE 564 20,886 0.027 
22 Malaysia Advanced IDC 95 3,905 0.024 
23 Indonesia Advanced IDC 19 817 0.023 
24 Argentina Advanced IDC 64 2,797 0.023 
25 Mexico OECD 129 6,320 0.020 
(*) G8: Group of 8; OECD: Organization for Economic Cooperation and Development; HIE:  High-Income 




The productivity of advanced IDCs is a relatively new phenomenon which may contribute to the 
relative lack of attention it has received.  Figure 1 shows the growth in numbers of US patents by 
inventors from several advanced IDCs* from 1990 through 2003 where the words drug, vaccine, 
or pharmaceutical appear in the patent abstract.16   The rate of patenting was relatively constant 




Figure 1: Selected countries' inventors'US patents in  















Figure 2 compares the two most active patenting IDCs, China and India, relative to Korea.  
Korea, has been an OECD country since 1995, and is often used as a benchmark for developing 
countries because its GDP per capita has grown exceptionally rapidly since 196017. 
 
( I think here and in table 3 above, it would be good to consider using the category of low, 
middle (low middle and upper middle), high income countries than the OECD or not; because 
Korea, Mexico, and Turkey are OECD members but they are classified as the upper middle 
income country: by the WB definition of per capital GDP less than 10,000 as of year 2000). 
Below in this paper on the World Health Organization’ launch of the National Regulatory 



















Citations of published articles are another proxy indicator of innovative capacity.  A recent 
analysis by King18 of highly cited publications from 1993-1997 and 1997-2001 also suggests a 
rapid increase in capabilities in advanced IDCs.  Comparing the two periods of the study, several 
IDCs increased the number of highly cited papers significantly and either exceeded or equaled 
the average percent increase in highly cited papers of all countries that were analyzed (Table 4). 
 
 
Table 4.  Numerical and Percent increases in the number 
of papers among the 1% most highly cited papers. 
Country Numerical increase Percent increase 
Brazil 88 88 
China 218 145 
India 93 83 
South Africa 30 59 
Top 30 countries average 112 59 
 
 
It is likely that for many of the IDCs, the impressive trends in patents and citations are a result of 
the recent and rapid increases in R&D investments, preceded by longer-term investments in 
science and engineering education.  According to a 1998 study, Argentina, Brazil, India, 
Malaysia, Mexico, Panama, Peru, the Philippines, Thailand, and Turkey allocated approximately 
$2.3 billion for health research for national needs.19  This number could be compared with the 
Figure 2: US drug, vaccine, or pharmaceutical patents for 
























budgets of the UK Medical Research Council ($0.3 billion) and the US National Institutes of 
Health ($10 billion) in 1998.20  Notably, this figure does not include China for which data were 
not available.  In developed countries the public and private sectors invest comparable amounts 
in health research, whereas in most developing countries the majority of health research is 
supported by the government and conducted in public institutions. 
 
Each of these countries, including China, is committed to double digit percent increases in health 
research funding.21, 22  We estimate total allocations in 2004 at no less than $3 billion.  For the 
fiscal year beginning April 2005, the Indian government alone plans to increase spending in all 
R&D to $3.3 billion, implying a minimum 15 percent increase in all major projects.23  The 
private biotechnology industry in India projects investments of $10 billion by 2010.24  Some 
developing countries are aggressively creating high quality pharmaceutical and biotechnology 
industries on their own initiative.25, 26 
 
Manufacturing and markets in developing countries are important components of innovation 
systems.   There is limited but growing evidence that IDC firms, if well networked and set up 
efficiently, are able to achieve significant cost advantages in production. 27  For example, a 
recent study by the Organization of Pharmaceutical Producers of India found a cost advantage of 
up to 50 percent compared with the United States.28  Further analysis is needed, and cost 
advantages may differ significantly between drug and vaccine manufacturers, but developing 
country cost-advantages arguably could lead to lower prices for products directed to the poor.  
South-South trade in low-cost products is an important aspect of access by the poor to both new 
and existing health interventions.  By value, 67% of India’s drug exports, 74% of Brazil’s and 
92% of Argentina’s go to other developing countries, while 63% of Uganda’s drug imports and 
54% of Tanzania’s drug imports by value come from other developing countries.29 
 
By volume, India is now the fourth largest producer of pharmaceuticals in the world (13th by 
value), the country holds 8% of the global pharmaceutical market by volume (1% by value), and 
India has the largest number of manufacturing facilities approved by the US Food and Drug 
Administration (FDA) anywhere outside of the United States.30  According to a recent analysis 
by the UK Department for International Development (DFID),31 China is now the 10th largest 
pharmaceutical market after Mexico (9th), and the second largest producer of pharmaceutical 
ingredients in the world.  For penicillin, vitamin C, terramycin, doxycycline and cephalosporin, 
China is the largest producer in the world.  The Serum Institute of India is now the largest 
manufacturer of diphtheria-pertussis-tetanus (DPT) vaccine in the world. 
 
According to the DFID study, 60% of UNICEF's vaccine requirements for the Expanded 
Programme on Immunization (EPI) are produced in just four countries:  India, Indonesia, Cuba 
and Brazil.  Thailand obtains 90% of its antiretroviral (ARV) ingredients from India, while the 
three South African producers of ARVs obtain 100% of their raw materials from India. 
 
“The Thai Public Health Ministry has clearly stated that their ambitious antiretroviral 
treatment programme would not exist without generic drugs, which would not have 
been possible without Indian [active pharmaceutical ingredient] supply.  ...Similarly, 
data from the Brazilian firm, Farmanguinhos, which supplies approximately 40% of 
the total [Brazilian] Ministry of Health ARV demand, shows that approximately 74% 
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of total ARV purchases in 2002 and 94% of total ARV purchases in 2003 were 
supplied by Indian, Chinese and Korean firms.”32 
  
 
A recent supplement of Nature Biotechnology, contains several papers emerging from a three-
year seminal study by the Canadian Program on Genomic and Global Health at the University of 
Toronto.26  The papers contain numerous examples of the growth of health innovation in 
developing countries.  For example, the number of exhibitors from developing countries 
attending the US Biotechnology Industry Organization’s annual conference grew from 2 in 2001 
to 97 in 2004.  In late 2003, the Chinese firm Shenzhen SiBono GenTech became the first in the 
world to obtain a license for a recombinant gene therapy product.  South Africa’s Council of 
Scientific and Industrial Research (CSIR) has isolated a hunger-suppressing steroidal glycoside 
(P57AS3) from an indigenous plant, Hoodia gordonii, and licensed the product to the British 
biotechnology firm, Phytopharm.  The Synthetic Antigen Laboratory at the University of Havana 
played a leading role in developing the world’s first human vaccine with a synthetic antigen. The 
vaccine protects against Haemophilus influenzae infection, which often leads to pneumonia and 
meningitis in children under the age of 5.  Made with a chemically produced antigen instead of 
fermented bacterial culture, it is much cheaper to produce and safer than vaccines coming from 
living organisms. 
 
Despite these impressive developments affecting innovation capabilities in developing countries, 
many impediments remain.  The Economist,33 reporting on the University of Toronto study, 
summarized some of specific problems in IDC health innovation systems: 
 
Brazil needs better links between academia and industry.  Egypt's budding 
biotechnologists are short of cash from both government and private sources.  India's 
regulatory system is slowing down product development.  South Africa needs to do 
more to reverse its brain drain, and train more researchers to boost their ranks.  
 
It is these impediments, and others, that an initiative focusing on innovation in developing 
countries will help to address.  Networking among developing countries is needed to share 
information and good practices for better alignment of national innovation policies and national 
health priorities.  Such an initiative will be essential if the growing health innovation capability 
of developing countries is to have an impact on public health. 
 
Is health innovation in developing countries likely to strengthen the fight against diseases of 
the poor? 
 
There is as yet insufficient understanding of the detailed nature, dimensions, trajectory, and 
potential impact of the revolution of innovation in developing countries, of whether and how this 
revolution can best address the needs of the poor.  Presumably, a significant portion of public 
sector investments by developing countries in health research is based on national health 
priorities.  These financial allocations require more in depth analysis to understand how they are 
being used, but it is clear that these countries are allocating large and increasing sums thereby 
providing the opportunity to allocate increasing amounts to research on diseases of the poor. 
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As emphasized by a recent UN Commission,34 the role of the private pharmaceutical industry in 
IDCs will be critical to success.  Will it be possible to obtain their commitment, to a meaningful 
extent, to working on diseases of the poor?  Most of the PD PPPs referred to earlier collaborate 
with pharmaceutical companies in developed countries, but none of these companies have 
prioritized diseases of the poor.35  The amount of in-house funds spent on diseases of the poor is 
insignificant compared to what is spent on their lead candidates – for cardiovascular, cancer, 
chronic diseases.36  Prioritizing the disease and health concerns of lucrative markets, for patients 
in the developed world, is understandable given all companies’ drive to maximize return-on-
investment.37, 38 
 
In one documented case, a major US manufacturer declined to participate in a meningitis vaccine 
development program directed to Africa even though the public sector partner was willing to 
invest up to $70 million in the effort.39  The manufacturer concluded that the funds available did 
not exceed the opportunity cost of directing its resources (financial, facilities and personnel) 
away from the more lucrative US market.  One of the conditions of participating in the 
meningitis program was that the price of the product not exceeded $1.00. 
 
According to the previously cited Indian private biotechnology investment projections, the R&D 
based private sectors in IDCs (as opposed to generics and material manufacture) are growing 
rapidly.  It is critical to recognize that all of these companies are driven to maximize a return on 
investment.  It is not surprising, then, that recent studies show that many of these companies are 
according priority to “diseases of the rich,” both locally and abroad.35  For example, in the patent 
data cited above, for all IDCs in 2003 only 10 of 105 drug, vaccine, or pharmaceutical patents 
issued were for diseases that predominantly affect the poor (three antivirals, one anti-malarial, 
two antibiotics for drug-resistant bacteria, two vaccines, and one treatment for vaginal infections). 
 
However, some IDC companies are considering business strategies that include diseases of the 
poor, and there are reasons to speculate that -- given their apparent cost and location advantages -
- they might be better placed to turn diseases of the poor into profitable business opportunities.40  
For example, the offer noted above by the meningitis program made good business sense to an 
Indian manufacturer after it was rejected by a US manufacturer.  The University of Toronto 
study of health biotechnology innovation systems in 7 developing countries found that health 
biotechnology in IDCs was often focused on local health needs, including import substitution 
(with lower cost products), manufacturing process improvements, and novel invention. 
 
Many IDC firms are now forming joint ventures with major international companies.  Examples 
include an R&D partnership between Ranbaxy Laboratories (India) and GlaxoSmithKline for 
product identification41 and, in Latin America, partnerships between Biomanguinhos/FIOCRUZ 
(Brazil) and Glaxo SmithKline for the production of Haemophilius influenzae vaccine, the 
Instituto Butantan (Brazil) and Aventis Pasteur for influenza vaccine, and the Instituto Finlay 
(Cuba) and Glaxo SmithKline for meningococcal group B vaccine.42 
 
The Study of Health Innovation Systems 
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Scholars who study innovation systems have, until very recently, paid little attention to health.  
However, Dhar and Rao have recently examined the development of the pharmaceutical industry 
in India.43  Their analysis identified key determinants of innovation. 
 
• Support for R&D.  The government provided extensive subsidies for R&D including tax 
concessions, soft loans and exemptions from price controls.  The government also 
provided extensive support of government research centers such as for the Council for 
Scientific and Industrial Research that actively engage in collaborative projects with 
private industry.  Beginning in the 1990s, the government developed policies to stimulate 
local public-private R&D partnerships for product development44.   
• Manufacture.  Until 1994, government policy required firms that were not using high 
technology in production of bulk drugs or formulations to limit their foreign holdings to 
40 percent to be considered Indian firms. 
• Intellectual property.  The Indian system recognized only process patents, excluding 
product patents for pharmaceuticals and agricultural chemicals from IP monopoly 
protection. 
• Domestic markets and exports.  This system allowed manufacturers to reverse engineer 
products that had been developed in the North -- both on and off patent -- for the 
domestic market.  Patented products could then enter international commerce as soon as 
the relevant patents had expired.       
 
The University of Toronto study45 identified the following main features of innovation.   
 
• Government policy:  Support for R&D.  Establishment and management of policies on 
intellectual property rights and drug regulation. 
 
• Public research institutes:  The growth of scientific institutions with highly trained staff, 
increasing number of paper published in international peer reviewed journals, capability 
to produce high quality products, formation of public-private partnerships, and 
development of products.   
 
• Industry:  The growth of private enterprise as reflected by increasing number of 
biotechnology firms, percent of the domestic market supplied by local firms, size of the 
domestic market, number of patents, and interest in public-private partnerships. 
 
• The general public:  The receptivity of the public to modern biomedical research 
particularly with respect to R&D involving genetics.   
 
These findings, as well as those of Da Motta e Albequerque and Cassiolato46, indicate that there 
are key determinants of health innovation systems in developing countries, and that 
strengthening these systems can help address national health priorities. 
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A Framework for understanding Health Innovation Systems 
In order better to understand health innovation systems in developing countries,9 and maximize 
their ability to address diseases of the poor, we propose a framework with six determinants.8,47, 
오류! 책갈피가 정의되어 있지 않습니다., 48, 49   
 
• Creating capacity for and undertaking R&D 
• Creating and sustaining capabilities to manufacture products to appropriate standards 
• Promoting and sustaining domestic markets 
• Promoting and sustaining export markets 
• Creating and implementing systems for IP management 
• Creating and implementing systems for drug, vaccine, diagnostic and device regulation 
 
Table 5 shows these six determinants in a framework, distinguishing characteristics of health 
innovation systems in three categories, from less to more advanced IDCs and, for comparison, 
developed countries as well50.  An essential aspect of this framework is that the six determinants 
are assumed to be dynamically linked such that progress in one is facilitated by and dependant 
upon progress in the others.51   Similarly, the lack of progress in one can impede progress in the 
other five.  Therefore, if a country wishes to shift from a less to a more advanced IDC category, 
it must make coordinated, dynamic progress in some or all of the determinants (in relation to 
their respective starting points). 
 
For example, it will be difficult to create an export market without a satisfactory national drug 
regulatory system.  Similarly, (and obviously) it will be difficult to develop new products from 
public or private R&D without a domestic ability for high quality manufacturing.  Publicly 
funded research also depends on sound public-private partnerships -- which ideally protect the 
public interest -- to translate academic findings into high quality products.52, 53  Finally, some 
argue that it will be difficult to attract significant private investments without a sophisticated 
intellectual property system to protect those investments and to achieve profitable returns. 
 
Experience from non-profit product development partnerships shows that IP rights can be used 
by the public sector to help attract private sector interest, mobilize the necessary funds, and 
ensure affordability and access to essential new health products.  There is therefore a need for 
special care in the development of national IP systems.  The most appropriate IP system for IDCs 
at different stages of development, particularly when viewed with a focus on diseases of the poor, 
depends on the underlying circumstances in each country remains an open question for policy 
research.  This point has been raised by many commentators, perhaps most notably by the UK 
Commission on IP Rights and the recent World Bank study.54
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Table 5.  Categories of health innovation systems in IDCs and developed countries by six determinants. 
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A Network to Strengthen Developing Country Capabilities 
In the complex field of new health product innovation, national governments, public and private 
sector product development efforts, and other related initiatives need to develop a coherent 
strategy for product development by addressing each of the determinants discussed above.  Some 
advanced IDCs may be able to address, and will address, all the determinants themselves.  
However, in other cases strategies involving coordination and learning among countries may be 
the best route.  South-South information exchanges could help countries learn from one another 
to maximize the effectiveness of their health innovation systems to both achieve economic 
development and to address national health priorities, including diseases of the poor. 
 
Developing countries with innovation capabilities could take on an important role of leading the 
global advocacy for health product innovation by sharing experiences, shaping priorities, 
developing workable strategies, conducting collaborative programs, and facilitating public-
private collaborations.  Such efforts would complement other initiatives including the PD PPPs 
which are primarily headquartered in developed countries (with numerous collaborative 
relationships in IDCs).55 
 
A South-South based initiative could help to promote research on health innovation systems (a 
heretofore neglected field), support the dissemination of information about effective innovations 
system policies among IDCs, promote the conduct of demonstration projects of innovation 
system policies concerning one or more of the determinants, and provide a forum for IDCs to 
exchange information about health innovation systems. There is a need to mobilize relevant 
institutions in developing countries that are concerned with health innovation including R&D 
centers, technology and IP management centers, drug and vaccine manufacturers, sources of 
financing, regulatory bodies, and government institutions and non-governmental organizations 
that are concerned with access to health products and services.  
 
As a mechanism to help strengthen health innovation systems in developing countries, this is 
consistent with key recommendations of previous studies that have examined the potential role 
of developing countries in health product innovation.  The Evans Commission of 1990 
highlighted that, in addition to addressing their own health needs, developing countries could 
contribute to the solution of global health problems.56  The UK Commission on Intellectual 
Property Rights has examined the issue of the participation of developing countries in health 
product innovation.57  The Commission’s report notes, “[Of important promise] might be a 
network of the public-private partnerships in developing countries, taking advantage of the 
concentration of research resources in public sector institutions but also the opportunity to build 
research capacity in the private sector.”  It then goes on to recommend: 
 
Public funding for research on health problems in developing countries should be 
increased.  This additional funding should seek to exploit and develop existing capacities 
in developing countries for this kind of research, and promote new capacity, both in the 




There are efforts underway to link and mobilize innovation in developing countries.  For 
example, the Global Forum for Health Research (GFHR) supports an annual meeting to bring 
together key individuals and organizations concerned with research on priority health problems 
in developing countries58 while the WHO-hosted Tropical Disease Research Special Programme 
has been a leader in this effort, and an ‘incubator’ of PD-PPPs.59  The Global Research Alliance 
(GRA), composed of nine research institutes in developed and developing countries, seeks to 
facilitate and promote research in a number of development areas including health.60  The 
Research Agency Collaborative for Global Health (REACH) is an emerging initiative to 
facilitate coordination and collaboration among national medical research agencies in both 
developed and developing countries.61  This year, the World Health Organization, along with 
nine developing countries, created and launched the National Regulatory Network for Vaccines.  
The participating countries are Brazil, China, Cuba, India, Indonesia, Russia, South Africa, 
South Korea and Thailand. 
 
Some new efforts have been created for, and led exclusively by, developing countries themselves.  
Each of these could be an important contributor to an international network promoting health 
product innovation in developing countries: 
 
• The Asia Pacific Economic Commission (APEC) is developing a comprehensive Strategic 
Plan for its Life Sciences Innovation Forum that addresses the issues raised in this 
paper.62 
• India-Brazil-South Africa Dialogue Forum (IBSA), established in June 2003, includes a 
focus on intellectual property and access to medicine, traditional medicine, and research 
and development of vaccines and pharmaceutical products to address national health 
priorities. 
• Technology Network for HIV/AIDS, announced during the 2004 Bangkok meeting on 
HIV/AIDS, includes Brazil, China, Nigeria, Russia, Thailand and Ukraine (and possibly 
South Africa and India in the near future).  The Network will support research and South-
South technology transfer on antiretroviral drugs and drug formulations, and the 
development of an HIV vaccine. 
• Developing Country Vaccine Manufacturers’ Association, established in 2000.63  
• The Third World Academy of Sciences, whose goal is “to promote scientific capacity and 
excellence for sustainable development in the South.” 
 
However, something more comprehensive seems to be needed.  The new initiative for health 
innovation systems in developing countries could help promote: 
 
• research on health innovation systems; 
• information sharing among IDCs; 
• information dissemination on effective policies and practices; 
• demonstration projects; and 
• capacity building to support all the above points. 
 
A major goal would be to help formulate policies in several areas including financing, capacity 
building in each of the determinants, and the formulation of laws and government regulations to 





Innovation systems research 
 
There is a real need to encourage studies focusing on diseases of the poor.  There is a need for 
innovation system theorists and global health practitioners to develop a more sophisticated 
literature on health innovation in developing countries.  Methodologies for country, product and 
company case studies, derived from innovation systems theory, need to be applied to health 
innovation.  This work would evaluate best policies and practices for consideration by IDCs.  
Another important product of this work would be the development of sustainable and consistent 
networks for information collection, analysis and sharing.   
   
Information dissemination 
There is a need to ensure the widest possible dissemination of best practices and polices 
identified through research and forum activities (see below) by, for example, codifying the 
output of innovation research into briefs for policy makers and practitioners. 
Demonstration projects 
There is a need to support demonstration projects to test implement of proposed policies and 
practices in real life situations, and to determine how best practices and policies may vary 
depending on local conditions. 
A Forum for IDCs 
These activities could be addressed to improve the efficiency and effectiveness of health 
innovation systems in IDCs through a forum that would bring together diverse institutions and 
individuals, including scientists, policy makers, and leaders from international development and 
the private sector.  Forum participants would: 
• discuss specific innovation determinants and share experiences related to innovation in 
health products, drawing on the health innovation research activities; 
• develop consensus on best practices and policies; and 
• advance policy initiatives to improve the efficiency and effectiveness of health product 
innovation. 
In 2003, The WHO Commission on Macroeconomics and Health called for an expanded outlay 
in 2007 of approximately $1.5 billion per year in R&D through a new Global Health Research 
Fund (GHRF).56   These funds would be in addition to those already allocated to existing 
channels such as the WHO-based research programs on tropical diseases and human 
reproduction, and the PD PPPs.  The report states, “A key goal of the GHRF would be to build 
long-term research capacity in developing countries themselves.  The GHRF would provide vital 
funding for research groups in low-income countries.”56 Unfortunately, developed countries have 
not implemented this recommendation perhaps, in part, due to a lack of appreciation of how 
rapidly capabilities for innovation in developing countries are growing. 
 
Arguably, those closest to the needs of the poor are the communities, scientists, policy makers, 
and institutions – public and private – in the countries where the challenges of poverty reside.  
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As persuasively argued by Lucas,64 it is essential to devise ways in which programs in developed 
countries can become better integrated with the scientific and technological institutions in 
developing countries that have been rapidly expanding their ability to undertake health 
innovation and are becoming part of the global knowledge economy.  Solutions depend on 
sophisticated global partnerships and collaborations to share knowledge and good practices in 
innovation policies to enable developing countries to drive and own agendas and harness their 
available capabilities to achieve the most effective ends including the improved health for the 
poor, and the generation of wealth. 
Conclusion 
To address global health disparities, the global community must harness the potential of national 
and regional health innovation systems throughout the world, with a particular focus on the 
development of technologies and techniques that are relevant to developing countries.65  This 
means making full use of abilities, energy and resources in both developed and developing 
countries.  Advanced IDCs should assume a leadership position in health innovation, both 
because of their increasing capacity to address global health problems, and because they are 
literally closer to the legitimate voices of those living in poverty.  A new focus on health 
innovation systems in developing countries should capture the imagination of those in leadership 
positions and many others who share the belief that all people, especially the disadvantaged, 
should be able to share equitably in the benefits of modern health innovation.  
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